AbbVie Inc (ABBV)vsHarmony Biosciences Holdings (HRMY)
ABBV
AbbVie Inc
$290.89
+1.68%
HEALTHCARE · Cap: $504.37B
HRMY
Harmony Biosciences Holdings
$38.50
+1.45%
HEALTHCARE · Cap: $2.21B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 6608% more annual revenue ($64.39B vs $959.90M). HRMY leads profitability with a 18.9% profit margin vs 9.8%. HRMY trades at a lower P/E of 12.2x. HRMY earns a higher WallStSmart Score of 75/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
HRMY
Strong Buy75
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.7%
Fair Value
$152.97
Current Price
$290.89
$137.92 premium
Intrinsic value data unavailable for HRMY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Strong operational efficiency at 34.2%
Revenue surging 30.3% year-over-year
Earnings expanding 88.2% YoY
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : HRMY
The strongest argument for HRMY centers on Operating Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 18.9% and operating margin at 34.2%. Revenue growth of 30.3% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : HRMY
The primary concerns for HRMY are Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while HRMY is a growth play — different risk/reward profiles.
HRMY carries more volatility with a beta of 1.01 — expect wider price swings.
HRMY is growing revenue faster at 30.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
HRMY scores higher overall (75/100 vs 73/100), backed by strong 18.9% margins and 30.3% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Harmony Biosciences Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?